Caris Life Sciences shareholders elect ten directors, ratify Deloitte as auditor for FY2026

Caris Life Sciences, Inc.

Annual Meeting held June 4, 2026; 273.7M shares represented (96.8% of 282.7M outstanding).
All ten director nominees elected with votes ranging from 200.4M to 228.7M in favor.
Deloitte & Touche LLP ratified as independent auditor: 273.5M for, 60.9K against, 136.3K abstentions.
Broker non-votes of 11.1M recorded on director election but not on auditor ratification.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.95

Caris Life Sciences, Inc. shareholders approved Election of ten director nominees to hold office until the 2027 Annual Meeting at the 2026-06-04 meeting.

Proposal: director election
Outcome: passed
Meeting: 2026-06-04

Exact text from the filing

Each of the following director nominees was elected to serve for a term expiring at the 2027 Annual Meeting by the votes set forth in the table below.

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.95

Caris Life Sciences, Inc. shareholders approved Ratification of appointment of Deloitte & Touche LLP as independent registered public accounting firm at the 2026-06-04 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2026-06-04

Exact text from the filing

The selection of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified by the shareholders by the votes set forth in the table below.

View on SEC.gov

995 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Caris Life Sciences, Inc. filing history →

Source: SEC EDGAR

accession 0002019410-26-000046

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.